Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2020; 26(36): 5474-5483
Published online Sep 28, 2020. doi: 10.3748/wjg.v26.i36.5474
Published online Sep 28, 2020. doi: 10.3748/wjg.v26.i36.5474
Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant
Anna Di Sessa, Giuseppina Rosaria Umano, Grazia Cirillo, Antonio Paride Passaro, Valentina Verde, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Department of Woman, Child and of General and Specialized Surgery, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
Domenico Cozzolino, Department of Internal Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy
Author contributions: Di Sessa A and Miraglia del Giudice E contributed to the research idea and study design; Guarino S, Umano GR, Passaro AP, and Verde V contributed to data acquisition; Cirillo G and Umano GR contributed to the molecular analysis; Marzuillo P, Miraglia del Giudice E and Cozzolino D contributed to the data analysis/interpretation; Di Sessa A and Marzuillo P contributed to statistical analysis; Miraglia del Giudice E and Marzuillo P contributed to supervision or mentorship. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.
Institutional review board statement: The study was approved by the Institutional Review Board of Università degli Studi della Campania Luigi Vanvitelli.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: Nothing to declare.
Data sharing statement: Datasets generated during analyses are available on request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Pierluigi Marzuillo, MD, PhD, Doctor, Postdoc, Postdoctoral Fellow, Department of Woman, Child and of General and Specialized Surgery, Università degli Studi della Campania Luigi Vanvitelli, Via Luigi De Crecchio 2, Napoli 80138, Italy. pierluigi.marzuillo@gmail.com
Received: April 1, 2020
Peer-review started: April 1, 2020
First decision: May 29, 2020
Revised: June 2, 2020
Accepted: September 4, 2020
Article in press: September 4, 2020
Published online: September 28, 2020
Peer-review started: April 1, 2020
First decision: May 29, 2020
Revised: June 2, 2020
Accepted: September 4, 2020
Article in press: September 4, 2020
Published online: September 28, 2020
Core Tip
Core Tip: Compelling evidence supports a genetic link between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease. In particular, both the major NAFLD risk polymorphisms such as the I148M polymorphism in the PNPLA3 and the E167K allele in the TM6SF2 gene affect renal function. Recently the rs72613567 variant in the HSD17B13 gene has been recognized as a novel genetic protective variant in the NAFLD scenario. We aimed to evaluate the effect of this variant on renal function in obese children.